R R Tasker1. 1. Division of Neurosurgery, Toronto Hospital, Ontario, Canada.
Abstract
BACKGROUND: The use of deep brain stimulation (DBS) at a site identical to that of thalamotomy is becoming increasingly popular for the control of tremor. It therefore seemed reasonable to compare the two operations. METHODS: A retrospective comparison was made of 19 DBS implants--16 for Parkinson's disease (PD), 3 for essential tremor (ET)--and 26 thalamotomies--23 for PD and 3 for ET--performed by the author with similar techniques between November 1, 1990 and July 1, 1996 and followed for at least 3 months. RESULTS: Complete tremor abolition occurred in 42% of both groups, near abolition in 79% and 69% respectively, recurrence in 5% and 15%, respectively. To achieve these results, 15% of thalamotomies, but no DBS implant, had to be repeated. Thus tremor recurrence after DBS can be controlled by stimulation parameter adjustment rather than by re-operation. A "microthalamotomy" effect from merely implanting an electrode, seen in 53% of cases and persisting for more than 1 year in five cases, prognosticated a good result and underlined the need for precision in target site selection. Ataxia, dysarthria, and gait disturbance were more common after thalamotomy (42%) than DBS (26%), but when they occurred after DBS they could nearly always be controlled by adjusting stimulation parameters. CONCLUSIONS: Thus, the flexibility of DBS for tremor control and complication avoidance makes it superior to thalamotomy for tremor control at the expense of equipment cost and continual management.
BACKGROUND: The use of deep brain stimulation (DBS) at a site identical to that of thalamotomy is becoming increasingly popular for the control of tremor. It therefore seemed reasonable to compare the two operations. METHODS: A retrospective comparison was made of 19 DBS implants--16 for Parkinson's disease (PD), 3 for essential tremor (ET)--and 26 thalamotomies--23 for PD and 3 for ET--performed by the author with similar techniques between November 1, 1990 and July 1, 1996 and followed for at least 3 months. RESULTS: Complete tremor abolition occurred in 42% of both groups, near abolition in 79% and 69% respectively, recurrence in 5% and 15%, respectively. To achieve these results, 15% of thalamotomies, but no DBS implant, had to be repeated. Thus tremor recurrence after DBS can be controlled by stimulation parameter adjustment rather than by re-operation. A "microthalamotomy" effect from merely implanting an electrode, seen in 53% of cases and persisting for more than 1 year in five cases, prognosticated a good result and underlined the need for precision in target site selection. Ataxia, dysarthria, and gait disturbance were more common after thalamotomy (42%) than DBS (26%), but when they occurred after DBS they could nearly always be controlled by adjusting stimulation parameters. CONCLUSIONS: Thus, the flexibility of DBS for tremor control and complication avoidance makes it superior to thalamotomy for tremor control at the expense of equipment cost and continual management.
Authors: R R Goodman; B Kim; S McClelland; P B Senatus; L M Winfield; S L Pullman; Q Yu; B Ford; G M McKhann Journal: J Neurol Neurosurg Psychiatry Date: 2006-01 Impact factor: 10.154
Authors: J S Anderson; H S Dhatt; M A Ferguson; M Lopez-Larson; L E Schrock; P A House; D Yurgelun-Todd Journal: AJNR Am J Neuroradiol Date: 2011-09-01 Impact factor: 3.825
Authors: Emily J Knight; Paola Testini; Hoon-Ki Min; William S Gibson; Krzysztof R Gorny; Christopher P Favazza; Joel P Felmlee; Inyong Kim; Kirk M Welker; Daniel A Clayton; Bryan T Klassen; Su-youne Chang; Kendall H Lee Journal: Mayo Clin Proc Date: 2015-06 Impact factor: 7.616
Authors: Claudio Da Cunha; Suelen L Boschen; Alexander Gómez-A; Erika K Ross; William S J Gibson; Hoon-Ki Min; Kendall H Lee; Charles D Blaha Journal: Neurosci Biobehav Rev Date: 2015-02-12 Impact factor: 8.989
Authors: Kelly E Lyons; Rajesh Pahwa; Cynthia L Comella; Mahmood S Eisa; Rodger J Elble; Stanley Fahn; Joseph Jankovic; Jorge L Juncos; William C Koller; William G Ondo; Kapil D Sethi; Matthew B Stern; Caroline M Tanner; Ron Tintner; Ray L Watts Journal: Drug Saf Date: 2003 Impact factor: 5.606